Quick Answer
Aclaris Therapeutics, Inc. reported Long-Term Debt of $10.65 million for fiscal year 2020.
Aclaris Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2020 | $10.65M | -64.4% |
| 2018 | $29.91M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| June 30, 2021 | $10.73M | +1.5% | +0.4% |
| March 31, 2021 | $10.69M | +1.1% | +0.4% |
| December 31, 2020 | $10.65M | — | +0.4% |
| September 30, 2020 | $10.61M | -64.5% | +0.4% |
| June 30, 2020 | $10.57M | -64.7% | +0.0% |
| March 31, 2020 | $10.57M | -64.7% | -64.7% |
| September 30, 2019 | $29.93M | — | +0.0% |
| June 30, 2019 | $29.92M | — | +0.0% |
- Aclaris Therapeutics, Inc. showed a decrease of -64.4% in Long-Term Debt compared to the prior fiscal year.
- Over the 2018–2020 period, Aclaris Therapeutics, Inc.’s long-term debt has declined by 64.4% (from $29.91 million to $10.65 million).
- The most recent figure is from Aclaris Therapeutics, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on February 24, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: